title: The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain.
abstract: In recent years a male group of anabolic-androgenic steroid misusers has been identified to share socio-demographic and personality related background factors with misusers of psychotropic substances, as well as being involved in habits of multiple drug use. The present study aimed to assess whether anabolic-androgenic steroids (AAS) would affect the density of the dopamine receptors in areas implicated in reward and behaviour in the male rat brain. The effects of 2 weeks of treatment with i.m. injections of nandrolone decanoate (15 mg/kg/day) on the expression of the D(1)-like and D(2)-like receptors were evaluated by autoradiography. Specific binding of D(1)-like receptors was significantly down regulated in the caudate putamen, the nucleus accumbens core and shell. D(2)-like receptor densities were down regulated in the nucleus accumbens shell, but up regulated in the caudate putamen, the nucleus accumbens core and the ventral tegmental area. These results are compatible with nandrolone induced neuroadaptive alterations in dopamine circuits associated with motor functions and behavioural paradigms known to be affected following AAS misuse.
authors.affiliation: Department of Pharmaceutical Biosciences, Division of Biological Research on Drug Dependence, Uppsala University, Box 591 Biomedicum, S-751 24 Uppsala, Sweden. Anna.Kindlundh@farmbio.uu.se
authors.forename: A M
authors.initials: AM
authors.lastname: Kindlundh
authors.forename: J
authors.initials: J
authors.lastname: Lindblom
authors.forename: L
authors.initials: L
authors.lastname: Bergström
authors.forename: J E
authors.initials: JE
authors.lastname: Wikberg
authors.forename: F
authors.initials: F
authors.lastname: Nyberg
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology*; D000818:Animals; D001345:Autoradiography; D001552:Benzazepines / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects*; D002540:Cerebral Cortex / Q000737:chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000737:chemistry / Q000187:drug effects; D018491:Dopamine Agonists / Q000378:metabolism / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism / Q000494:pharmacology; D007457:Iodine Radioisotopes; D008032:Limbic System / Q000737:chemistry / Q000187:drug effects; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000077603:Nandrolone Decanoate; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000032:analysis*; D017448:Receptors, Dopamine D2 / Q000032:analysis*; D012457:Salicylamides / Q000378:metabolism / Q000494:pharmacology; D013378:Substantia Nigra / Q000737:chemistry / Q000187:drug effects
chemical_list: C049558:8-iodo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol; D045930:Anabolic Agents; D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007457:Iodine Radioisotopes; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D009277:Nandrolone; D000077603:Nandrolone Decanoate; C064246:NCQ 298